Genethon, which developed the lentiviral vector used and sponsored initial clinical studies, is pleased with the conclusive results of the gene therapy trial underway in the United States and England in X-linked Chronic Septic Granulomatosis (X-CGD), a rare and severe immune dysfunction. Six of the nine patients are free of treatments related to complications generated by the disease. These results have been published in Nature Medicine. Genethon who had conducted initial preclinical and clinical studies had formed a strategic alliance with the British company Orchard therapeutics which has an exclusive license on G1XCGD for the further clinical development of this gene therapy drug.

Read more